RE: questions per my postCS...helpful insights and confirmation. Again, appreciated.
As soon as someone posted in mid December Endo had started recruitment of Ph3b (Cat?) I must admit I have not been as happy about a recent BNC-related event since the announcement of the Endo agreement. Your statement below is where my head has been and the essence of my very first post on this board (if memory serves)...
"You could bet your boots that had (a) failed, (b) wouldn't be happening right now, irrespective of what some might say...."
The Milestone payment for Ph3a was of course right up there (and, arguable more important), but its lack of clarity (and associated $ figure) muddled its importance and meaning and hence how it was appreciated (for me).
I also agree the first quarter of 2011 should be a stellar once Endo begins to communicate 3a results (not to mention some other potential happenings). But, I have learned to manage expectations with BNC so as long as I see/ hear the fundamentals unfolding then I remain confident everything else will fall into place.
Thanks again and if others can provide further input (to questions below)...much appreciated! rg
Previous response to CS's prior post....On a different note: thanks for sharing the info in your most recent post re Endo agreement: subsection 1.70 and your interpretation/comment... "Net net, first PIII was successful, period."
Questions: Would you (or other posters) be able to provide a reasonable $ estimate of what the "total cost" to Endo will be for the "new" PhIII clinical trial assuming its full completion (including costs for approval for Europe)? And, a related and "naive question"...Would there be any reason that Endo proceed with the new trial if initial PhIII was not successful?